Definitions
Sorry, no definitions found. You may find more data at protect.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word PROTECT.
Examples
-
The bad thing is that more and more firefighters are being hurt and killed trying to friggin 'PROTECT these morons that build where they shouldn't!
Bound to lose David 2006
-
The legislation is called the PROTECT IP Act PIPA, and would put us in legal jeopardy if we linked to a site anywhere online that had any links to copyright infringement.
-
The legislation Mr. Schmidt opposed is called the PROTECT IP Act in the U.S. Senate and the Stop Online Piracy Act in the U.S. House of Representatives.
-
Just before Congress went on vacation in August 2007, the President, Mr. McConnell and their minions in Congress used a fake threat of an imminent terrorist attack to frighten the Senate and the House of Representatives into passing (with very little scrutiny and brief whimpering) a six-month revision of FISA called the PROTECT AMERICA ACT OF 2007 (PAA of 2007).
The Powerful and Obnoxious Odor of Mendacity: FISA and the Bill of Rights 2008
-
ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial.
DWS Full News Feed 2010
-
ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe
-
The study, known as PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11, is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and biologic activity of PROVENGE in men with non-metastatic androgen-dependent prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate.
-
ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase 2/3 multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease.
-
ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease.
-
The study, known as PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11, is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and biologic activity of PROVENGE in men with non-metastatic androgen-dependent prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.